Company: SRPT
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0000950170-25-083131
Chunk: 1

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-06-06
Form: 8-K
Item: Item 5.07
Chunk 1
---
Item 5.07. Submission of Matters to a Vote of Security Holders.

The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal. As of the record date for the Annual Meeting, April 8, 2025, there were 98,256,898 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 84,586,114 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 86.09% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business.

Proposal 1: Election of Directors

The director nominees listed below were elected to serve on the Company’s board of directors as members of Class II for a term of two years. The results of the vote were as follows:

  Name of Nominee                         For        Against      Abstain      Broker Non-Votes                  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Richard J. Barry                 64,757,685      9,565,547       60,768            10,202,114                  
  M. Kathleen Behrens, Ph. D.      69,004,024      5,336,943       43,033            10,202,114                  
  Stephen L. Mayo, Ph. D.          73,289,653      1,051,656       42,691            10,202,114                  
  Claude Nicaise, M. D.            71,006,475      3,334,914       42,611                            10,202,114  

Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2024. The results of the advisory vote were as follows:

         For        Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────
  72,144,292      2,176,998       62,710            10,202,114  

Proposal 3: Amendment to the Company’s 2018 Equity Incentive Plan

The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows:

         For        Against      Abstain